Relutrigine is filed as an NDA for developmental and epileptic encephalopathy. The PDUFA date sits 22 days out. A hospital pharmacy has not received a Relutrigine shipment from that file. Praxis is the listed name on the file. None of that is a commercial product.
A PDUFA date is a clock. A shelf is a shipment.
Twenty Form 4 buys in ninety days do not shorten 22 days. They do not turn an NDA into a drug that exists outside a folder. The useful sentence on the next Praxis print is whether Relutrigine is still the NDA, still the indication, and still in the 22-day class of clock, or whether the file has been refused, withdrawn, or moved into a later year. A bid in the name while the file is quiet does not grade the file. A later date on the same molecule is a delay. It is still a folder.
Relutrigine is still an NDA for developmental and epileptic encephalopathy, 22 days from a PDUFA date. Praxis is the listed name on the file. Twenty Form 4 buys do not turn that folder into a hospital-pharmacy product. A later date on the same molecule is a delay. An approval that names a different indication is a different file.
Relutrigine is the file. The 22-day clock does not make a product.